BUSINESS

Pfizer Wringing Hands over PMP Eligibility for Lorlatinib; It Might Earn 1st Conditional OK, but It’s “4th” ALK Inhibitor

July 5, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Will Pfizer Japan’s next-generation ALK inhibitor lorlatinib qualify for the price maintenance premium (PMP) scheme for innovative medicines? The drug might bag the country’s first conditional drug approval as early as this autumn, but its fourth-in-class status in the ALK…

To read the full story

Despite Being 4th in ALK Class, Lorbrena Qualifies for PMP as It Gets 5% Pricing Premium
November 14, 2018
Japan’s 1st Conditional OK Might Come This Autumn for Pfizer’s Next-Gen ALK Inhibitor Lorlatinib
June 13, 2018

BUSINESS

Shionogi/F2G’s Novel Antifungal Makes Mark, New Option in Resistant Cases
June 19, 2026
Axcelead Joins Lilly’s TuneLab AI Drug Discovery Platform
June 19, 2026
Create BioVentures Sets Sail as Drug Discovery Bridge Builder
June 19, 2026
Merck Japan Expands Fertility Benefits, Raises Lifetime Cap to 18 Million Yen
June 19, 2026
Santen CEO Paid 251 Million Yen in FY2025, COO Joins Disclosure List
June 19, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…